Pancreatic cancer incidence and outcome in relation to ABO blood groups among Han Chinese patients: a case-control study
Pancreatic cancer incidence and outcome in relation to ABO blood groups among Han Chinese patients: a case-control study
复制标题
DOI：
10.1002/ijc.25426
复制
发表时间：
2011-03-01
影响因子：
6.4
通讯作者：
Li, Zhaoshen
中科院分区：
文献类型：
--
作者：
Ben, Qiwen;Wang, Kaixuan;Li, Zhaoshen
本研究的目的是确定中国汉族人群中 ABO 血型与胰腺导管腺癌 (PDAC) 风险和进展之间的关系。 2000年至2009年期间，两家大学附属医院招募了1,431名PDAC患者和1,449名年龄和性别匹配的对照者。使用无条件多变量逻辑回归分析来估计调整后的优势比（OR）。还分析了患者 ABO 血型与临床病理特征之间的关系。与血型 0 的受试者相比，A 型或 AB 型血的病例的风险稍高，调整后的 OR（95% 置信区间）分别为 1.368 (1.127-1.661) 和 1.391 (1.053-1.838)。非 O 型血（A、B 或 AB）患者的肿瘤 TNM 分期比 0 型血患者的肿瘤晚期程度更高（p < 0.001）。在接受潜在治愈性手术的患者中，0 型血患者的中位生存时间明显长于非 O 型血患者（16.0 个月 vs. 11.0 个月，p = 0.001，对数秩检验）。这项研究显示了血型类型与 PDAC 发生和进展风险之间存在关联的证据。这些发现值得在针对汉族患者的大型人群前瞻性研究中得到进一步证实。
The aim of the current study was to determine the association between ABO blood group and the risk and progression of pancreatic ductal adenocarcinoma (PDAC) in the Han Chinese ethnic group. During the period of 2000-2009, 1,431 patients with PDAC and 1,449 age- and sex-matched controls were recruited in two university-affiliated hospitals. An unconditional multivariable logistic regression analysis was used to estimate adjusted odds ratios (ORs). The relationship between patient ABO blood group and clinicopathologic features was also analyzed. Compared with subjects having blood group 0, a modestly higher risk was observed among cases with blood group A or AB with adjusted ORs (95% confidence interval) of 1.368 (1.127-1.661) and 1.391 (1.053-1.838), respectively. The TNM stages of tumors in patients with non-O blood groups (A, B or AB) were more highly advanced than in patients with blood group 0 (p < 0.001). Among patients who underwent a potentially curative operation, the median survival time of patients with blood group 0 was significantly longer than that of patients with non-O blood groups (16.0 months vs. 11.0 months, p = 0.001, log-rank test). This study shows evidence of an association between blood group type and risk for development and progression of PDAC. These findings merit further confirmation in a large population-based prospective study in patients of the Han Chinese ethnic group.